- Home
- VIGL vs OFS Comparison
VIGL vs OFS Comparison
Compare VIGL & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- OFS
- Stock Information
- Founded
- VIGL 2020
- OFS 2001
- Country
- VIGL United States
- OFS United States
- Employees
- VIGL N/A
- OFS N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- OFS Finance/Investors Services
- Sector
- VIGL Health Care
- OFS Finance
- Exchange
- VIGL Nasdaq
- OFS Nasdaq
- Market Cap
- VIGL 95.2M
- OFS 107.9M
- IPO Year
- VIGL 2022
- OFS 2012
- Fundamental
- Price
- VIGL $2.08
- OFS $8.07
- Analyst Decision
- VIGL Strong Buy
- OFS
- Analyst Count
- VIGL 5
- OFS 0
- Target Price
- VIGL $19.75
- OFS N/A
- AVG Volume (30 Days)
- VIGL 331.7K
- OFS 62.6K
- Earning Date
- VIGL 11-07-2024
- OFS 03-03-2025
- Dividend Yield
- VIGL N/A
- OFS 16.83%
- EPS Growth
- VIGL N/A
- OFS N/A
- EPS
- VIGL N/A
- OFS N/A
- Revenue
- VIGL N/A
- OFS $49,799,000.00
- Revenue This Year
- VIGL N/A
- OFS N/A
- Revenue Next Year
- VIGL N/A
- OFS N/A
- P/E Ratio
- VIGL N/A
- OFS N/A
- Revenue Growth
- VIGL N/A
- OFS N/A
- 52 Week Low
- VIGL $1.49
- OFS $7.75
- 52 Week High
- VIGL $6.06
- OFS $12.07
- Technical
- Relative Strength Index (RSI)
- VIGL 55.12
- OFS 46.22
- Support Level
- VIGL $1.79
- OFS $8.00
- Resistance Level
- VIGL $2.02
- OFS $8.15
- Average True Range (ATR)
- VIGL 0.16
- OFS 0.14
- MACD
- VIGL 0.08
- OFS 0.00
- Stochastic Oscillator
- VIGL 96.72
- OFS 57.14
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.